Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - vardenafilhydrochloridtrihydrat - filmovertrukne tabletter - 10 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - vardenafilhydrochloridtrihydrat - filmovertrukne tabletter - 20 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - vardenafilhydrochloridtrihydrat - filmovertrukne tabletter - 5 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - vardenafilhydrochloridtrihydrat - filmovertrukne tabletter - 10 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - vardenafilhydrochloridtrihydrat - filmovertrukne tabletter - 20 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - vardenafilhydrochloridtrihydrat - filmovertrukne tabletter - 5 mg

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

laboratoire aguettant - noradrenalintartrat - infusionsvæske, opløsning - 0,08 mg/ml

Taani - taani - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - sevofluran - væske til inhalationsdamp

Euroopa Liit - taani - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatid - osteoporose - calciumhomeostase - sondelbay is indicated in adults. behandling af osteoporose hos postmenopausale kvinder og hos mænd med øget risiko for brud. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. behandling af osteoporose, der er forbundet med vedvarende systemisk glukokortikoid behandling, kvinder og mænd med øget risiko for fraktur.

Euroopa Liit - taani - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - calciumhomeostase - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.